On Mar. 23, 2020, CSL announced that it was exploring development of a hyperimmune serum that could be derived from the blood plasma of people who have recovered from coronavirus.

Once an adequate number of recovered patients was identified, CSL could begin to collect their plasma and create a hyperimmune serum enriched with COV-19 antibodies to use as a therapy.